Literature DB >> 9692547

Identification of PTEN/MMAC1 alterations in uncultured melanomas and melanoma cell lines.

H Tsao1, X Zhang, E Benoit, F G Haluska.   

Abstract

A novel tumor suppressor gene, PTEN/MMAC1, has been recently shown to be mutated in gliomas, breast, prostate, kidney cancers and melanomas. Loss-of-heterozygosity studies in melanoma have suggested the presence of at least one chromosome 10q locus lost early in tumor progression. In this study, we screened 45 melanoma cell lines and 17 paired uncultured metastatic melanoma and peripheral blood specimens for PTEN/ MMAC1 alterations using PCR-SSCP and direct sequencing. We found nine melanoma cell lines with homozygous deletions (five with intragenic loss) and four cell lines with mutations (one nonsense and one frameshift; two intronic); from among our uncultured melanoma specimens, we found one tumor with a somatic 17 bp duplication in exon 7 leading to a premature stop codon and one tumor with a possible homozygous deletion. Furthermore, we have identified a novel intragenic polymorphism within intron 4 of PTEN/MMAC1. Taken together, these data suggest that PTEN/MMAC1 may be a chromosome 10q tumor suppressor important in melanoma tumor formation or progression.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9692547     DOI: 10.1038/sj.onc.1201881

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  66 in total

Review 1.  Melanoma: from mutations to medicine.

Authors:  Hensin Tsao; Lynda Chin; Levi A Garraway; David E Fisher
Journal:  Genes Dev       Date:  2012-06-01       Impact factor: 11.361

2.  Epigenetic PTEN silencing in malignant melanomas without PTEN mutation.

Authors:  X P Zhou; O Gimm; H Hampel; T Niemann; M J Walker; C Eng
Journal:  Am J Pathol       Date:  2000-10       Impact factor: 4.307

Review 3.  Genetic alterations of PTEN in human melanoma.

Authors:  Almass-Houd Aguissa-Touré; Gang Li
Journal:  Cell Mol Life Sci       Date:  2011-11-11       Impact factor: 9.261

Review 4.  Oncogenic mutations of PIK3CA in human cancers.

Authors:  Yardena Samuels; Todd Waldman
Journal:  Curr Top Microbiol Immunol       Date:  2010       Impact factor: 4.291

Review 5.  Driver mutations in melanoma: lessons learned from bench-to-bedside studies.

Authors:  Janice M Mehnert; Harriet M Kluger
Journal:  Curr Oncol Rep       Date:  2012-10       Impact factor: 5.075

6.  PTEN activation through K163 acetylation by inhibiting HDAC6 contributes to tumour inhibition.

Authors:  Z Meng; L-F Jia; Y-H Gan
Journal:  Oncogene       Date:  2015-08-17       Impact factor: 9.867

Review 7.  Therapeutic targets in melanoma: map kinase pathway.

Authors:  Frank G Haluska; Nageatte Ibrahim
Journal:  Curr Oncol Rep       Date:  2006-09       Impact factor: 5.075

Review 8.  Targeting the PI3-kinase/Akt/mTOR signaling pathway.

Authors:  Burhan Hassan; Argun Akcakanat; Ashley M Holder; Funda Meric-Bernstam
Journal:  Surg Oncol Clin N Am       Date:  2013-08-06       Impact factor: 3.495

9.  Elucidating the mechanism of miRNA-214 in the regulation of gingival carcinoma.

Authors:  Yu Gong; Hongli Yang; Xin Tian
Journal:  Exp Ther Med       Date:  2017-03-24       Impact factor: 2.447

10.  AXL/AKT axis mediated-resistance to BRAF inhibitor depends on PTEN status in melanoma.

Authors:  Qiang Zuo; Jing Liu; Liping Huang; Yifei Qin; Teresa Hawley; Claire Seo; Glenn Merlino; Yanlin Yu
Journal:  Oncogene       Date:  2018-03-19       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.